1Analysis of the current status and trends in recombinant protein vaccine research and developmentXU Li, LI Huan, LIU Min, LI Xiao-jing, HE Wu2577-25842Application of platform technology and regulatory considerations for innovative monoclonal antibody productsQIU Xiao, WANG Wen-bo, YANG Fei, ZHANG Meng-meng, GONG Xu, WEI Wei2585-25883Advances in artificial intelligence-driven neoantigen prediction algorithmLI Qian, WANG Xue, JIN Xiang-wan-er, KOU Ya-zhen, HUANG Ying, HE Wu2589-25974Quality risk management and considerations on evaluation of stem cell-derived pancreatic islet cell medicinal productsLIU Dan, LU Jia-qi, YIN Hui-fang, WEI Wei2598-26045Pharmaceutical technical requirements and prospects for cell-based regenerative medicine therapeutic drugsHAN Dong-mei, DONG Jing, WEI Wei2605-26096Analysis of common issues in quality control and evaluation of mesenchymal cell therapeutic drugsWEI Wei, CHENG Su-yuan, HAN Dong-mei, HE Wu2610-26157Research progress and pharmaceutical considerations on therapeutic cancer vaccinesWANG Xue, LI Qian, YANG Fei, HE Wu2616-26218CMC evaluation considerations for tumor-infiltrating lymphocyte in clinical trial applicationCUI Jing, WANG Xue, WEI Wei2622-26289Post-approval CMC submissions and regulatory considerations for autologous CAR-T cell productsWANG Jing-yu, WANG Xue, LU Jia-qi, WEI Wei2629-263410Requirements for re-registration of biological products in ChinaYUAN Rong-rong2635-263811General considerations for the development and similarity evaluation of dulaglutide biosimilarsHU Ying-ying, CHENG Su-yuan2639-264512Interpretation of the"Technical Guideline for Platform Validation of Viral Clearance Processes in Clinical Trial Applications for Therapeutic Recombinant Protein Products"HU Ying-ying, SAI Wen-bo2646-265113Regulatory considerations for replacing in vivo bioactivity assays with in vitro methods for recombinant glycoprotein hormonesLI Yi-jun, WEI Wei, CHENG Su-yuan2652-265614Considerations on establishing quality standards of specific human immunoglobulin productsJIA Yan-hua, JIA Dong-chen, YU Peng-li, WU Zhou-yi2657-265915Thoughts on common problems in pharmaceutical review of enzyme replacement therapy biologics for rare diseasesKAN Hong-jin, CHENG Su-yuan2660-266716Recent advances in the development and regulatory pharmaceutical evaluation of dual-payload antibody-drug conjugatesCHEN Hao, LI Qian, WEI Wei2668-267317Considerations for elemental impurity control strategies of recombinant protein products based on ICH Q3D(R2)KOU Ya-zhen, WEI Wei, HE Wu2674-267918Common issues and review considerations for the packaging systems of therapeutic recombinant biological productsWU Yong-kai, LI Qian, WEI Wei, HE Wu2680-2685 